BRIACELL THERAP (BCTX) vs Context Therapeutics Inc. (CNTX)

BRIACELL THERAP and Context Therapeutics Inc. are both Biotechnology companies. BRIACELL THERAP and Context Therapeutics Inc. are of similar size ($37.2M and $34.1M). Context Therapeutics Inc. has negative trailing earnings, so its P/E is not meaningful; BRIACELL THERAP trades at 1.9×. Across the 9 metrics below, Context Therapeutics Inc. leads on 5 and BRIACELL THERAP on 4.

Valuation

Metric BCTX CNTX Biotechnology median
P/E 1.94 n/m 7.88
P/S n/m n/m 11.47
P/B 1.34 0.87 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m 0.20 0.74
EV/Sales n/m n/m 10.73
Earnings yield 51.65% (137.14%) (28.84%)
Free cash flow yield (100.28%) (102.14%) (23.03%)

Profitability

Metric BCTX CNTX Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (173.55%) (76.14%) (57.72%)
Return on assets (139.20%) (68.96%) (49.22%)
Return on invested capital (3,311.00%) 0.00% 0.00%

Growth

Metric BCTX CNTX Biotechnology median
Revenue growth (TTM) — — 5.64%
EPS growth (last fiscal year) (43.04%) 17.39% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BCTX CNTX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.07 5.81 4.73
Net debt to EBITDA 0.66 1.66 0.96

Dividend

Metric BCTX CNTX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric BCTX CNTX Biotechnology median
Market cap 37.24m 34.10m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack